Drug discovery has traditionally been a reductive process—narrowing down, filtering out, and optimizing within established constraints. Generative AI turns that on its head. It is an expansive force, ...

VANCOUVER, BC / ACCESS Newswire / November 25, 2025 / Variational AI, a leading innovator in generative artificial intelligence for drug discovery, is making headlines in biotech with a bold mission: ...

Variational Autoencoders (VAEs) are an artificial neural network architecture to generate new data. They are similar to regular autoencoders, which consist of an encoder and decoder. The encoder takes ...

Although the potential applications of quantum computing are widespread, a new feasibility study suggests quantum computers ...

Merck & Co. Inc., (NYSE:MRK) is one of the best conservative stocks to buy now. On September 23, the company confirmed a strategic collaboration with Variational AI to leverage its Enki Platform in ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research ...

Merck & Co. has partnered with Variational AI to explore using artificial intelligence in drug discovery. Variational AI CEO Handol Kim says Merck will test Variational’s Enki platform in finding new ...

Variational AI CEO Handol Kim's company has a platform that uses the language of chemistry to create drug recipes | Rob Kruyt Multinational drug developer Merck is partnering with a Vancouver-based ...